A novel metallocarboxypeptidase inhibitor was isolated from the medical leech Hirudo medicinalis. Amino acid sequence analysis provided a nearly complete primary structure. which was subsequently verified and completed by cDNA cloning using reverse transcriptasepolymerase chain reaction/rapid amplification of cDNA end techniques. The inhibitor, called LCI (leech carboxypeptidase inhibitor), is a cysteine-rich polypeptide composed of 66 amino acid residues. It does not show sequence similarity to any other protein except at its C-terminal end. In this region, the inhibitor shares the amino acid sequence -Thr-Cys-X-Pro-Tyr-Val-X with Solanacea carboxypeptidase inhibitors, suggesting a similar mechanism of inhibition where the C-terminal tail of the inhibitor interacts with the active center of metallocarboxypeptidases in a substrate-like manner. This hypothesis is supported by the hydrolytic release of the C-terminal glutamic acid residue of LCI after binding to the enzyme. Heterologous overexpression of LCI in Escherichia coli, either into the medium or as an intracellular thioredoxin fusion protein, yields a protein with full inhibitory activity. Both in the natural and recombinant forms, LCI is a tightly binding, competitive inhibitor of different types of pancreatic-like carboxypeptidases, with equilibrium dissociation constants K i of 0.2-0.4 ؋ 10 ؊9 M for the complexes with the pancreatic enzymes A1, A2, and B and plasma carboxypeptidase B. Circular dichroism and nuclear magnetic resonance spectroscopy analysis indicate that recombinant LCI is a compactly folded globular protein, stable to a wide range of pH and denaturing conditions. In recent years, there has been an increasing interest in the role of proteases in various biological processes such as peptide processing, defense mechanisms, fertilization, carcinogenesis, trauma, inflammation, and coagulation/fibrinolysis, among others (1-3). The biological actions of most proteases is controlled by the interaction with specific proteinaceous inhibitors. In contrast to the wide variety of structurally diverse inhibitors regulating the activity of endoproteinases (4), only a few specific inhibitors that form tight complexes with carboxypeptidases have been identified (5). The only metallocarboxypeptidase inhibitors described so far are the 38 -39-residue proteins from Solanacea (potato and tomato) (6), a 65-residue protein from Ascaris suum (7), and, more recently, a 223-residue protein from rat brain (8). The proteins from Solanacea and Ascaris inhibit carboxypeptidases by a common mechanism where their C-terminal tail interacts with the target enzymes in a substrate-like manner. The C terminus of the mammalian inhibitor from rat brain, however, does not seem to be a suitable substrate for carboxypeptidases (8); this protein is thought to interact with carboxypeptidases by a small region that shows sequence similarity to the inhibitory loop in the propeptides of these enzymes. This inhibitor region may bind in a fashion similar to the long (94 -96 residues) N-terminal propeptides of the carboxypeptidase zymogens (9 -11), which fold as independent globular domains and position their inhibitory loop on top of the active site cleft of the enzymes.
In recent years, there has been an increasing interest in the role of proteases in various biological processes such as peptide processing, defense mechanisms, fertilization, carcinogenesis, trauma, inflammation, and coagulation/fibrinolysis, among others (1) (2) (3) . The biological actions of most proteases is controlled by the interaction with specific proteinaceous inhibitors. In contrast to the wide variety of structurally diverse inhibitors regulating the activity of endoproteinases (4) , only a few specific inhibitors that form tight complexes with carboxypeptidases have been identified (5) . The only metallocarboxypeptidase inhibitors described so far are the 38 -39-residue proteins from Solanacea (potato and tomato) (6), a 65-residue protein from Ascaris suum (7) , and, more recently, a 223-residue protein from rat brain (8) . The proteins from Solanacea and Ascaris inhibit carboxypeptidases by a common mechanism where their C-terminal tail interacts with the target enzymes in a substrate-like manner. The C terminus of the mammalian inhibitor from rat brain, however, does not seem to be a suitable substrate for carboxypeptidases (8) ; this protein is thought to interact with carboxypeptidases by a small region that shows sequence similarity to the inhibitory loop in the propeptides of these enzymes. This inhibitor region may bind in a fashion similar to the long (94 -96 residues) N-terminal propeptides of the carboxypeptidase zymogens (9 -11) , which fold as independent globular domains and position their inhibitory loop on top of the active site cleft of the enzymes.
Several proteinaceous inhibitors of serine proteases have been isolated from leeches (12) . Leech-derived inhibitors include anticoagulants such as the thrombin-specific hirudins and the factor Xa-specific antistasin (13) , and other serine protease inhibitors with a biological function not fully understood. We have now isolated, sequenced, cloned, expressed, and characterized a novel carboxypeptidase inhibitor from the medical leech Hirudo medicinalis. The newly characterized protein, named LCI 1 (for leech carboxypeptidase inhibitor), the first carboxypeptidase inhibitor found in leeches. LCI does not show similarity in sequence with any other carboxypeptidase inhibitor except at its C-terminal end, suggesting a mechanism of inhibition similar to that of the inhibitors from Solanacea and Ascaris.
EXPERIMENTAL PROCEDURES
Materials-Pharmaceutical extracts from the medical leech H. medicinalis were a gift from G.E.N. Therapeutica (Bad Zwischenahn, * This work was supported in part by Acciones Integradas SpainGermany Grant HA96-0027; by Grants BIO95-0848 and BIO98-0362 from the Comisión Interministerial de Ciencia y Tecnología, Ministerio de Educación, Spain; by the Center of Reference for Biotechnology (Generalitat de Catalunya, Spain); and by Sonderforschungsbereich 469 from Ludwig-Maximilians-Universitä t Munich. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence (s) Germany). Bovine CPA was from Boehringer Mannheim; porcine CPB and human CPA2 were prepared following described procedures (14, 15) . Trypsin (tosyl-L-phenyl chloromethyl ketone-treated) was from Worthington. The synthetic carboxypeptidase substrates benzoyl-glycyl-L-phenylalanine, benzoyl-glycyl-L-arginine, carbobenzoxy-glycyl-Ltryptophan, furyl-acryloyl-L-phenylalanyl-L-phenylalanine, and furylacryloyl-L-alanyl-L-lysine were from Sigma and Bachem. Restriction enzymes, ligases and nucleases were from Boehringer Mannheim, New England Biolabs, and Invitrogen.
Purification of LCI-Lyophilized leech extract (ϳ0.5 g) was dissolved in 20 mM Tris acetate (pH 8.0) buffer, and the insoluble residues were removed by centrifugation at 13,000 ϫ g for 10 min. After pH equilibration, the supernatant was loaded onto a preparative anion-exchange column (TSK-DEAE 5PW, 2.5 ϫ 15 cm; Toyo-Soda) connected to a FPLC system (Amersham Pharmacia Biotech), and elution was performed with a linear gradient from 0% to 100% 0.8 M ammonium acetate in 20 mM Tris acetate at a flow rate of 4 ml/min for 80 min. Fractions were collected and analyzed by CPA inhibition tests. Inhibitor-containing fractions were lyophilized and subjected to reverse-phase HPLC (Vydac C4 column) using a linear gradient from 20% to 42% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 1 ml/min for 60 min. The purity of the isolated inhibitor was checked by SDS-Tricine gel electrophoresis (16) and N-terminal sequence analysis.
Determination of the Molecular Mass-The molecular masses of the natural and recombinant forms of the inhibitor were analyzed using the MALDI-TOF mass spectrometry technique. MALDI-TOF mass spectra were acquired on a Bruker Biflex spectrometer equipped with a pulsed nitrogen laser (337 nm), in linear or reflectron, positive ion mode, and using a 19-kV acceleration voltage. Synapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) or ␣-cyano-4-hydroxicinnamic acid were used as matrix for the analysis of intact proteins or isolated peptide fragments, respectively. Samples were prepared by mixing equal volumes of a saturated solution of the matrix in 0.1% trifluoroacetic acid in water/ acetonitrile 2:1 and a peptide solution of a concentration (range, 1-10 M). From this mixture, 1 l was spotted on the sample slide and allowed to evaporate to dryness.
Reduction, Carboxymethylation, and Proteolytic Cleavage-LCI in 50 mM Tris (pH 8.0) was denatured and reduced by addition of 5 M guanidinium HCl and 5 mM dithiothreitol for 1 h at 37°C. Carboxymethylation of cysteines was achieved by addition of 10 mM iodoacetic acid for 30 min at room temperature in the dark. The solution was diluted five times with 0.15 M ammonium hydrogen carbonate (pH 8.0) and treated with trypsin (Worthington) or with V8 endoproteinase (Glu-C endoproteinase from Staphylococcus aureus) for 14 h at 37°C and at 20:1 ratio (w/w). The reactions were stopped by adding the same volume of 0.1% trifluoroacetic acid in water. Peptide fragments resulting from the enzymatic digestions were purified on a Waters HPLC system using a Vydac C18 column eluted with a linear gradient from 15% to 60% acetonitrile in 0.1% trifluoroacetic acid in 80 min (1 ml/min). The carboxymethylated inhibitor and the isolated peptide fragments were analyzed by automated amino acid sequencing on a Beckman LF3000 Protein Sequencer and by MALDI-TOF mass spectrometry.
Molecular Cloning of the LCI cDNA-Gene-specific degenerated oligonucleotides designed based on the N-terminal and internal amino acid sequence of purified LCI, oligonucleotides for cDNA synthesis, and 3Ј-rapid amplification of cDNA ends (RACE) primers were synthesized by MWG-Biotech (Ebersberg, Germany): N1, 5Ј-GACGAATCNTTYYT-NTGYTAYCA-3Ј with N ϭ A, C, G, or T and Y ϭ C or T (deduced from amino acids 5-12 of LCI); N2, 5Ј-TGTGCTAYCARCCNGAYCARGT-3Ј with R ϭ A or G (from amino acids 9 -16); N3, 5Ј-CCAGACCARGTNT-GYTGYTTYAT-3Ј (from amino acids [13] [14] [15] [16] [17] [18] [19] [20] ; C1, 5Ј-CCTGTGSWRTA-NGGNACCCA-3Ј with S ϭ G or C and W ϭ A or T (from amino acids 55-49); YXT, 5Ј-CGAGGGGGATGGTCGACGGAAGCGACCT 18 -3Ј (modified from Ref. 17); Y, 5Ј-CGAGGGGGATGGTCGACGG-3Ј (representing a part of YXT); X, 5Ј-GATGGTCGACGGAAGCGACC-3Ј (representing a part of YXT).
Total RNA was isolated from frozen leeches using the guanidinium thiocyanate procedure (18), and poly(A) ϩ RNA was purified by oligo(dT) affinity separation (Amersham Pharmacia Biotech). First-strand cDNA synthesis (Amersham Pharmacia Biotech) was carried out with the oligonucleotide YXT as primer. "Nested" PCR was performed to amplify an internal cDNA fragment and for 3Ј-RACE; in a first round of PCR, leech cDNA was amplified using the gene-specific primers N1, N2, and N3 in all combinations with the gene-specific primer C1 or the adaptor primers X and Y. PCR mixtures were diluted 20-fold, and re-amplified using all combinations of appropriate nested primers. PCR amplifications were performed with 25 pmol of both primers and the Goldstar polymerase (Eurogentec, Belgium), using 30 cycles each with 94°C for 20 s, annealing at 53°C for 1 min, and extension at 72°C for 2 min. PCR products were separated by electrophoresis on 1.8% agarose/Tris acetate gels. Prominent PCR products generated by amplifications with the primer pairs N3/C1 and N3/X were eluted from the gel, subcloned using the pGEM-T AT-cloning system (Promega) and used to transform Escherichia coli strain JM109 by electroporation to generate the clones pGEM-LCI-N3/C1 and pGEM-LCI-N3/X. Subsequently, the 5Ј end of the LCI-cDNA was obtained by a 5Ј-RACE approach using the Marathon cDNA amplification kit (CLON-TECH). Briefly, after second strand cDNA synthesis and adapter ligation "semi-nested" PCR was performed with the Marathon adaptor primer AP1 and the gene-specific primers 5Ј-TAGTCAAGAAGAGAAA-TGCCCT-3Ј and 5Ј-TTAGCCTCGCATCAGTGACACACG-3Ј (complementary to nucleotides 361-340 and 300 -277 of the complete cDNA; see Fig. 3 ) in the first and second round of PCR, respectively. PCR products were analyzed and subcloned as described above.
Synthetic cDNA 5Ј End and Heterologous Expression of LCI-A twostep PCR strategy was used to append the 5Ј bases, which code for the N-terminal amino acids of mature LCI, to the partial LCI-cDNA obtained by 3Ј-RACE. Three oligonucleotides were designed using E. coli codon usage and synthesized by Amersham Pharmacia Biotech: A, 5Ј-GAAAGCTTCCTGTGCTATCAGCCAGACCAGGTGTGCTGTTTC-3Ј; B, 5Ј-ATCCCATACCCCGGATGAAAGCTTCCTGTGCTATCAGC-3Ј; C, 5Ј-ATTGGATCCTTACTACTCGACATATGGGATGC-3Ј.
PCR was first performed using primers A-C and the plasmid pGEM-LCI-N3/X as template. Subsequently, the product was used as template for a second PCR with primers B and C. Amplifications were performed using Vent polymerase (New England Biolabs) and 30 cycles each with 94°C for 45 s, annealing at 50°C for 2 min, and extension at 72°C for 2 min. PCR products were analyzed by 3% methaphor agarose/Tris acetate gel. The final product of the two-step PCR was digested with BamHI prior to ligation with the expression vectors.
For heterologous expression of LCI, the vectors pIN-III-OmpA3 (19) and pET-32b (Promega) were used. pIN-III-OmpA3 was cleaved with EcoRI, blunt-ended with Mung bean nuclease (Boehringer Mannheim), and digested with BamHI. This linearized vector, having a blunt and a BamHI end, was ligated with the final product of the two-step PCR (see above) to generate the plasmid pIN-III-OmpA3-LCI, which was used to transform E. coli strain MC1061. Similarily, pET-32b was cleaved with EcoRV and BamHI to generate a linearized vector with a blunt end and a BamHI end, and ligated with the PCR product to generate pET-32b-LCI. This plasmid was used to transform E. coli strain ADA494, a thioredoxin reductase (trxB) mutant that allows the formation of disulfide bonds in the E. coli cytoplasm.
For the production of recombinant LCI, 5 ml of MC1061/pIN-IIIOmpA3-LCI inoculum were grown overnight at 37°C in M9CAS (containing 0.3% glycerol) and used to inoculate 0.5 liter of the same medium. After growth for 2 h, IPTG was added to a final concentration of 0.5 mM. At 24 h after induction, the culture was centrifuged at 10,000 ϫ g for 20 min, and the supernatant was applied to a Sep-Pak Plus C18 cartridge (Waters, Millipore). The bound material was eluted with 40 ml of 30% 2-propanol and concentrated in a Roto-Vapor to remove the organic solvent. Subsequently, recombinant LCI was purified essentially as described above for LCI from leech extracts.
5 ml of ADA494/pET-32b-LCI were grown overnight in Luria-Bertani (LB) medium and used to inoculate 0.5 liter of the same medium. When the optical density of the culture reached values of 0.4 -0.6, IPTG was added to a final concentration of 0.4 mM. At 3 h after induction, recombinant LCI produced intracellularly as a thioredoxin fusion protein was purified using Ni 2ϩ affinity chromatography. After sonication of cells in binding buffer (5 mM imidazol, 0.5 mM NaCl, 20 mM Tris/HCl, pH 7.9) the supernatant was loaded onto a Hi-trap Ni 2ϩ column (Amersham Pharmacia Biotech). The LCI-thioredoxin fusion protein bound to the column via its histidine tag was eluted with 1 M imidazol, 0.5 M NaCl, 20 mM Tris/HCl, pH 7.9. Subsequently, the fusion protein was cleaved with enterokinase (Sigma), and the recombinant LCI purified as described above.
Enzymatic Measurements-The general assay for carboxypeptidase inhibition was carried out by preincubation of 10-l samples with 5 l of bovine CPA1 (0.1 mg/ml in 50 mM Tris/HCl, 0.5 M NaCl, pH 7.5) for 5 min at room temperature, followed by the addition of 1 ml of the substrate furyl-acryloyl-L-phenylalanyl-L-phenylalanine (0.2 mM) and measurement of the absorbance change at 330 nm. In specific assays for different carboxypeptidases, the following substrates were used: benzoyl-glycyl-L-phenylalanine for bovine CPA1, benzoyl-glycyl-L-arginine for porcine CPB, carbobenzoxy-glycyl-L-tryptophan for human CPA2, and furyl-acryloyl-L-alanyl-L-lysine for plasma CPB; substrate hydrol-ysis was monitored at 254 nm (for CPA1 and CPB) or 300 -304 nm (CPA2). Equilibrium dissociation constants (K i ) for the complexes of LCI and rLCI with the different carboxypeptidases were determined essentially as described (20, 21) for tightly binding inhibitors. Experimental details were identical to those described for potato carboxypeptidase inhibitor analysis (22, 23) . Briefly, after preincubation of constant concentrations of an enzyme with increasing concentrations of the inhibitor (I t ) and measuring the residual enzymatic activities (v o to v i ), linear plots of
were obtained at five or more different substrate concentrations. The derived slopes were plotted as function of the substrate concentration, the intersection with the y axis giving the K i value.
Circular Dichoism and NMR Analysis of LCI-Circular dichroism (CD) analysis were carried out in a Jasco J-715 spectrometer, at 15 M rLCI concentration in 15 mM phosphate buffer, at different pH values and temperatures. Reduction and/or denaturing conditions were achieved by treating LCI with 5 mM dithiothreitol during 24 h or dissolving rLCI in 8 M urea. NMR spectra were obtained in a 400-MHz Bruker AMX spectrometer, with rLCI at 1 mg/ml in 15 mM phosphate buffer, at different pH values and temperatures; spectra were obtained both in normal and deuterated (99.9%) water after dissolution of freezedried samples.
RESULTS

Purification, Mass Determination, and Protein Sequence
Analysis of LCI-The purification of LCI from leech extract is summarized in Fig. 1 . Using anion-exchange chromatography to fractionate the pharmaceutical leech extracts, carboxypeptidase inhibitory activity was detected in two fractions eluting at ϳ64 min and ϳ69 min (Fig. 1A) . After desalting and acidification, these fractions were subjected to reverse-phase HPLC (Fig. 1, B and C, respectively) , where proteins with inhibitory activity eluted at retention times of ϳ38 and ϳ34 min, respectively. Both protein species inhibit carboxypeptidases similarly, with a K i -value of ϳ0.4 nM for bovine pancreatic carboxypeptidase A1 (at pH 7.5).
The two inhibitor species were analyzed by automated Edman degradation and MALDI-TOF mass spectrometry. In both cases, the sequence NH 2 -SHTPDESFLCYQPDQVCCFICR-GAAPLP was obtained for the N-terminal 28 residues, suggesting that both inhibitor species comprise very similar or identical proteins. However, mass spectrometry revealed different molecular masses of 7326 and 7197 Da for the earlier and latter HPLC-eluting inhibitor species, respectively (Fig. 1D) .
After reduction and carboxymethylation, both inhibitor species were fragmented with trypsin and V8-protease and peptide maps were obtained by reverse-phase HPLC and MALDI-TOF mass spectrometry. Nearly identical peptide maps were generated, suggesting identity in sequence along most of the molecules. This was confirmed by separation of peptides using reverse-phase HPLC, followed by the determination of their masses and amino acid sequences. The resulting overlapping peptides (Fig. 2) cover the entire sequence of LCI. The entire sequence was subsequently confirmed by cDNA cloning (see below).
MALDI-TOF mass spectrometry was also performed after treatment of oxidized and reduced LCI with the carboxymethylating agent iodoacetic acid, and showed an incorporation of zero and of eight carboxymethyl groups, respectively. Thus, all eight cysteine residues of LCI appear to be involved in disulfide bond formation.
Cloning and Sequence Analysis of LCI cDNA-Molecular cloning of the LCI cDNA was accomplished by amplification of an internal fragment combined with RACE (17, 24, 25) . Genespecific external (N1, N2, and N3) and internal (C1) degenerated primers were designed based on the N terminus and an internal peptide sequence of LCI, respectively.
First strand cDNA, synthesized from H. medicinalis poly(A) ϩ RNA primed with the oligonucleotide YXT, was used as template for a first PCR with the gene-specific primers N1, N2, and N3 in combinations with the specific primer C1 or the 3Ј-RACE primers X and Y (which represent parts of the oligonucleotide YXT); no bands were visualized on agarose gels from this PCR. The amplification mixtures were used as templates for a second round of PCR with all combinations of nested primers. Prominent PCR products of about 120 and 380 base pairs were generated in several reactions by amplification with the primer combinations N3/C1 and N3/X, respectively, purified, and subcloned. Sequence analysis of the plasmids showed The different peptides, obtained by hydrolysis of the reduced and carboxymethylated inhibitor with either trypsin or V8 endopeptidase followed by reversephase HPLC purification, were submitted to automated Edman degradation analysis and to MALDI-TOF mass spectrometry. The 28-residue N-terminal sequence was obtained by direct analysis of uncleaved inhibitor. The overlapping of peptide sequences was facilitated/confirmed by the parallel knowledge of the nucleotide sequence of LCI (shown in Fig. 3) .
the presence of an internal and a 3Ј-cDNA fragment, respectively (i.e. nucleotides 103-230 and 103-465 of the complete cDNA; see Fig. 3 ). This partial cDNA sequence was used to design several primers for 5Ј-RACE. A ϳ350-base pair fragment was amplified by seminested PCR and subcloned. Five clones were sequenced, which contain fragments representing nucleotides 1-300 of the complete cDNA of LCI; they consistently differ from the 3Ј-RACE clones by the three non-coding base pair exchanges G111A, G114T, and C240T.
The LCI mRNA, as deduced from the overlapping cDNA clones (Fig. 3) , contains an uninterrupted open reading frame of 243 nucleotides, which is preceded by a 21-nucleotide 5Ј-untranslated sequence and followed by a 182-nucleotide 3Ј-untranslated region. A hexanucleotide AATAAA consensus signal for polyadenylation is found 15 nucleotides before the poly(A) ϩ tail. The size of this LCI mRNA is consistent with that of a single ϳ500-nucleotide transcript detected by Northern blot analysis of total leech RNA (data not shown). Preliminary results from Southern blot analysis of leech DNA suggest that the leech genome contains a single copy of the LCI gene (Fig. 4) .
Translation of the open reading frame of the LCI mRNA generates an 81-amino acid sequence containing a 15-residue hydrophobic signal peptide, which precedes the N-terminal Ser of the mature protein. Computer search analysis with the entire LCI did not show any sequence similarity with other known proteins. The deduced 66-residue sequence of mature LCI is in complete agreement with that of the protein purified from leech extracts. The molecular mass predicted for mature LCI, assuming the formation of four S-S bonds, is 7322 Da and coincides with the value determined for one of the two inhibitor species purified from leech extracts. Furthermore, sequence and mass spectrometry data suggest that the accompanying 7197-Da species corresponds to a C-terminally truncated LCI (i.e. des-Glu 66 -LCI, see below). This would also explain its different behavior in anion exchange and reverse-phase chromatography. The truncation most likely is the consequence of proteolytic processing by carboxypeptidase action (see below).
Heterologous Expression of LCI-A two-step PCR strategy was designed to generate the 5Ј-bases that are missing in the partial LCI cDNA obtained by 3Ј-RACE and code for the 12 N-terminal amino acid residues of mature LCI. The resulting cDNA was subsequently ligated into the expression vectors pIN-III-OmpA3 and pET-32b (see "Experimental Procedures" for details).
The expression plasmid pIN-III-OmpA3-LCI was used to transform E. coli MC1061 (26), a strain previously utilized for the recombinant production of the potato carboxypeptidase inhibitor (22) . Initial expression assays were performed in shaker flasks, and the culture medium as well as the periplasmic and cytoplasmic fractions were analyzed for the presence of the recombinant inhibitor (rLCI). rLCI was found almost exclusively in the culture medium, suggesting that the OmpA signal peptide directed the immature protein through the plasma membrane into the periplasmic space with concomitant removal of the signal peptide, and subsequent release of mature rLCI through the outer membrane into the culture medium.
For optimization of rLCI production, different culture conditions were examined. pIN-III-OmpA3-LCI was grown in M9CAS medium supplemented with different amounts of glycerol (0.3, 0.6, and 1%), and 0.5 or 1 mM IPTG was used for induction; rLCI in culture supernatants was quantified by measurements of CPA inhibition. Highest expression yields were obtained in cultures with 0.3% glycerol and 0.5 mM IPTG, suggesting that an excess of glycerol in the medium inhibits the expression of rLCI. This result is in agreement with previous findings using similar expression systems (22) . Approximately 3.4 mg of rLCI per liter of supernatant were produced in shaker flasks, yielding a 60% recovery after purification. Recombinant LCI was purified essentially as described for LCI from leech extracts. N-terminal amino acid sequence analysis (GSHT-PDE . . . ) and MALDI-TOF mass spectrometry (7383 Da) verified that rLCI is correctly processed and contains a construction-added glycine residue as the N-terminal residue.
Larger quantities of rLCI were obtained using the pET-32b-LCI/E. coli ADA494 expression system (27) to produce an intracellular fusion protein of thioredoxin covalently linked to the N terminus of LCI. The fusion protein was rapidly and efficiently purified by Ni 2ϩ affinity chromatography, yielding 20 -40 mg of thioredoxin-LCI/liter of E. coli medium. A rLCI species with four additional amino acid residues at the Nterminal end (NH 2 -A-M-A-I-LCI) and inhibitory properties virtually identical to those of the naturally occurring inhibitor was released by digestion of the fusion protein with enterokinase.
Selectivity of LCI for Different MetallocarboxypeptidasesEquilibrium dissociation constants (K i ) for the complexes of rLCI with different metallocarboxypeptidases were determined at pH 7.5. rLCI is a tightly binding, competitive inhibitor of pancreatic carboxypeptidases with different specificities, i.e. Table I ). Preincubation of the inhibitor with the enzymes for various periods of time did not affect its inhibitory activity, suggesting that rLCI is a fast binding and stable inhibitor.
The effect of metallocarboxypeptidases on rLCI was studied by incubation of equimolar amounts of rLCI and bovine carboxypeptidase A1, followed by MALDI-TOF mass spectrometry. Within a few minutes, the C-terminal residue of LCI (Glu 66 ) was released, without detectable change of residual enzyme activity measured in parallel experiments. Thus, the inhibitory activity of LCI is not significantly affected by the removal of the C-terminal residue. Moreover, des-Glu 66 -rLCI, isolated after treatment of rLCI with bovine carboxypeptidase A1, inhibits the enzyme with a K i virtually identical to that determined for the uncleaved inhibitor (ϳ0.2 nM). The complex of des-Glu 66 -rLCI with carboxypeptidase A1 appears to be stable, as no recovery of carboxypeptidase activity or further cleavage of LCI were detected even after long incubation periods (days). A similar removal of the C-terminal residue has been reported for PCI (6) , which is thought to interact with the protease in a substrate-like manner. Surprisingly, removal of Glu 66 was also observed after incubation of rLCI with pancreatic carboxypeptidases A2 or B, which have a restricted specificity for aromatic or positively charged C-terminal residues, respectively.
Conformation-dependent Properties of LCI-Sequence-based predictions (28) suggest that the secondary structure elements of LCI are mainly restricted to the cysteine-containing sequence (i.e. residues 10 -61), and that this region should be rich in ␤-structures and in loops. The CD spectrum of rLCI is quite peculiar, with a strong minimum of ellipticity at 210 nm and a maximum at 228 nm (Fig. 5) . The former band may be related to the presence of a high percentage of residues in ␤-structure, and the latter to both ␤-structures and loops (29) or to an asymmetric environment of Tyr 64 (see "Discussion"). CD measurements at different pH values show that LCI essentially keeps the same structure at pH 3.0, 6.5, and 11; the spectra obtained at the two lower pH values are practically identical, and a shift of the 228-nm band is observable at pH 11 that could be related to the titration of Tyr
64
. The 210-and 228-nm bands keep most of their intensity when the temperature is raised from 25°C to 85°, and the native spectrum is completely recovered when temperature is returned back to 25°C. Treatment with 8 M urea decreases the absorbance of the 228-nm band, this effect being stronger when denaturation is carried out at pH 3.0 and at high temperature. Dialysis removal of urea leads in all cases to the recover of the original ellipticity value. The 228-nm band disappears, however, if the protein is reduced at pH 8.0 with 5 mM dithiothreitol, and it does not fully recover after elimination of the reductant.
Proton nuclear magnetic resonance (NMR) analysis of rLCI showed spectra with a large dispersion of resonances at both the low and high fields, with a significant number of potential methyl protons in the 0 -1 ppm region, and rich in exchangeable resonances in the NH region, suggesting a globular compactly folded structure (Fig. 6) . A significant resistance of NH protons to exchange was detected when raising the temperature in the range of 25-95°C in both H 2 O and D 2 O conditions; moreover, the 0 -1.0 ppm protons, although downfield-shifted, were still spread and visible at high temperatures. Taken together, these results indicate a high thermostability of the protein, which requires temperatures above 85°C to unfold. DISCUSSION We have isolated and characterized a novel proteinaceous carboxypeptidase inhibitor from the medical leech H. medicinalis, named LCI. LCI is a 66-residue single-chain polypeptide rich in cysteines (8 residues, as half-cystines) and prolines (9 residues). It does not show significant identity in sequence with other proteins except at its C terminus; in this region LCI shares the sequence -Thr-Cys-X-Pro-Tyr-Val-X with carboxypeptidase inhibitors from Solanacea (see Fig. 7) . A lower degree of sequence similarity exists between the C-terminal ends of LCI and the carboxypeptidase inhibitor from A. suum, despite the closer evolutionary relationship of leeches to this intestinal worm than to plants and the more similar size of the proteins (66 and 65 residues, respectively, compared with 38 -39 residues).
Two forms of LCI differing in the presence of the C-terminal amino acid residue Glu 66 were isolated from leech extracts. C-terminally truncated inhibitor forms have previously been found during the purification of hirustasin and leech-derived tryptase inhibitor from leech extracts (30, 31) . Most likely, these inhibitor species result from the removal of the last amino acid(s) of the mature proteins by carboxypeptidases prior to or during purification. Full-length and truncated LCI have virtually identical carboxypeptidase inhibitory activity so that both species may coexist in leeches as biological fully active inhibitor proteins.
The complete cDNA of LCI (Fig. 3) was deduced from three overlapping cDNA clones obtained by RACE approaches. It contains an open reading frame coding for an 81-residue protein containing a hydrophobic signal sequence (15 residues) preceding the mature LCI, and verifies the sequence obtained by amino acid analysis of the isolated inhibitor as well as the presence of a C-terminal Glu residue. A signal peptide cleavage site is predicted between Ser 15 and Ser 16 (32) , corresponding to the N terminus of mature LCI isolated from leeches.
For heterologous expression, a semisynthetic gene coding for mature LCI was constructed from a 3Ј-RACE clone by reconstruction of the missing 5Ј base pairs; E. coli codon usage was applied to facilitate the production in E. coli systems. LCI was efficiently expressed in E. coli; the inhibitory properties of the recombinant protein are virtually identical to those of the naturally occurring inhibitor, confirming that the cDNA translation product is correctly folded and functionally equivalent to the protein purified from leeches.
Both CD and NMR studies suggest that rLCI is a highly structured molecule of globular and compact nature. It appears to maintain a well folded conformation in a wide pH and temperature range, and is remarkably resistant against denaturation by both high concentrations of urea and elevated temperatures. The CD spectra suggest a high percentage of residues in ␤-structure under mild conditions. However, CD spectra of disulfide-rich molecules like LCI are difficult to interpret due to the occurrence of anomalous dichroic bands such as that at 228 nm (29) . This band can also be potentially assigned to Tyr 64 of LCI, in analogy to a similar CD band attributed to the asymmetric environment of Tyr 37 in the C-terminal tail of the PCI. 2 On the basis of this assumption, the C-terminal residues of LCI, which most likely comprise the predominant site of interaction with carboxypeptidases, may have a restricted mobility in a fashion similar to PCI (33, 34) . LCI appears to fold in a globular core of 52 residues (the region between the first and last cysteines) with tails of 9 and 5 residues at the N and C terminus, respectively. The core is likely to be rich in loops, as suggested by the presence of 7 proline and 8 half-cystine residues. Several reasons support the hypothesis that the C-tail of LCI, i.e. the sequence -Ile-Pro-Tyr-Val-Glu, is the primary inhibitory site for metallocarboxypeptidases. First, the Pro-TyrVal triad is conserved in the C-tails of LCI and the potato and tomato carboxypeptidase inhibitors (-Pro-Trp-Gly in the A. suum inhibitor) (Fig. 7) . For PCI, this triad has been shown to interact with the S2 and S3 subsites of carboxypeptidase A1 by x-ray crystallography (35) . Furthermore, we have previously shown by site-directed mutagenesis (23) that the Val residue is essential for the binding of PCI to the enzyme, contributing more than one third to the binding energy of the inhibitor. The C-terminal residue of both PCI and LCI (Gly and Glu, respectively) is immediately cleaved after binding to carboxypeptidases, without loss of inhibitory activity of the proteins after trimming. X-ray crystallographic analysis (35) indicates that, after trimming, the newly generated C-terminal residue of PCI (i.e. Val 38 ) has its carboxylate co-ordinated to the catalytic zinc of carboxypeptidase A1, thus clearly contributing to inhibition. A similar conformational arrangement yielding an equivalent effect may be expected for the complexes of LCI with metallocarboxypeptidases.
The similarity of the potential primary contact region of LCI with that of PCI suggests that its C-tail is not highly mobile but keeps a preferred orientation to facilitate binding with carboxypeptidases as seen in PCI (33, 35, 36) . This would require the establishment of weak interactions between the C-tail and the protein core. The core may also play an important role by 2 G. Venhudova and F. X. Avilés, unpublished results. providing secondary binding region(s) to the enzyme, as shown for PCI (35) . In this respect, the lower K i -values of the complexes of different metallocarboxypeptidases with LCI compared with those with PCI (0.2-0.4 nM and 1.5-5 nM, respectively; see Table I and Ref. 23) suggest that the larger core of LCI (nearly twice the size of that of PCI) facilitates the establishment of additional or more efficient secondary contacts with the enzymes.
The presence of a C-terminal -Thr-Cys-X-Pro-Tyr-Val-X sequence in two evolutionary highly distant proteins such as the carboxypeptidase inhibitors from leeches and Solanacea, the lower degree of similarity with the Ascaris carboxypeptidase inhibitor, and the lack of sequence identity within the remainders of these molecules may suggest that this C-terminal tail is the consequence of convergent evolution dictated by the threedimensional structures of the receptor molecules, i.e. the metallocarboxypeptidases. The mechanism of inhibition by these proteins is distinct from that suggested for the carboxypeptidase inhibitor from rat brain (8) , which may bind to the enzymes with a small internal region, probably mimicking the inhibition mechanism described for the pro-segments of metallocarboxypeptidases (5, 9, 37) .
LCI is the first carboxypeptidase inhibitor identified in leeches. A variety of structurally diverse inhibitors of serine proteinases have previously been purified from leeches (12) , most prominently among them the thrombin-specific hirudins and the factor Xa-specific antistasins, anticoagulants that are required to maintain the liquid state of the blood during feeding and inside the leech. Potentially, LCI may participate in the elimination of blood clots by inhibiting plasma carboxypeptidase B, an enzyme recently been shown to retard fibrinolysis (38, 39) . In addition, LCI may inhibit the hydrolysis of kinins by metallocarboxypeptidases at the site of the bite, thus prolonging kinin-induced increased blood flow and edema formation and facilitating the sucking of the leech.
The biological functions of other leech-derived inhibitors, e.g. 1) the bdellins, inhibitors of trypsin and plasmin (40) ; 2) the eglins, inhibitors of leukocyte elastase, cathepsin G, and mast cell chymase (41); 3) hirustasin, an inhibitor of tissue kallikrein and cathepsin G (30, 42) ; and 4) the leech-derived tryptase inhibitor (31, 43) are not yet understood. Interestingly, the medical leech contains inhibitors directed against all proteases of human mast cells, i.e. tryptase, chymase, cathepsin G, and carboxypeptidase A. Considering that mast cells are activated and release their granule-associated enzymes during parasitic infections (44 -47) , it is conceivable that these inhibitors, including LCI, are produced by leeches to block host defense mechanisms initiated by the mast cell proteases.
